First in Patient Study for PF-06840003 in Malignant Gliomas

Status:
Terminated

Trial end date:
2018-12-26

Target enrollment:

Participant gender:

This study will evaluate the safety and tolerability of increasing doses of PF-06840003 in patients with malignant gliomas.

Phase 1

Pfizer